Skip to main content

Biotech Research AI: Protecting Novel IP in AI-Assisted Discovery

Biotech research organizations want AI to accelerate target review, assay interpretation, literature synthesis, experiment planning, and investor-ready summaries. The governance problem is that the most valuable prompts are often the least safe to expose: unpublished target hypotheses, screening results, platform-method details, compound IDs, and translational notes. Keeptrusts helps when you treat novel IP protection as a routing and audit problem first, not as a fantasy detector problem. data-routing-policy, rbac, dlp-filter, pii-detector, hipaa-phi-detector, and audit-logger give you a practical boundary around discovery assistants.

Use this page when​

  • You are using AI in biotech research for target evaluation, assay analysis, scientific drafting, or internal discovery support.
  • You need to keep pre-patent IP and patient-linked translational data off unmanaged provider routes.
  • You want a route design that is reviewable and enforceable instead of relying on researcher discretion.

Primary audience​

  • Primary: Technical Leaders
  • Secondary: Technical Engineers, Research platform and security teams

The problem​

Many biotech AI programs overestimate semantic controls and underestimate route design. The organization wants to know whether the system can recognize novel science automatically and block it perfectly. In practice, the safer question is simpler: which users can access which route, and which providers are allowed to see which data class? If you get that wrong, even a strong detector stack will not save you.

Biotech workflows also mix research IP with health-adjacent data. Translational medicine prompts may include cohort notes, biomarker summaries, or investigator language that pulls the route into healthcare governance territory. That means a discovery assistant can be an IP-protection workflow and a privacy workflow at the same time.

The last challenge is proof. Boards, investors, partners, and internal research leads often want more than a promise that the team “used a secure model.” They want to know whether the route was local or zero retention, whether identifiers were stripped, and whether the assistant was accessed only by approved roles. Without an event trail, those questions become unproductive debates.

The solution​

The safest biotech pattern is to use route isolation as the primary control and content filtering as a backstop. data-routing-policy should express the provider boundary directly. For highly sensitive discovery work, that usually means self-hosted or tightly controlled targets first. rbac ensures the route is tied to named identities instead of lab-shared credentials. dlp-filter catches compound IDs, assay patterns, or study codes you know about. audit-logger then makes the whole path reviewable.

When the route handles translational or clinical-research material, add pii-detector and hipaa-phi-detector so patient-linked content is redacted before provider routing. That is what turns a discovery assistant into a serious operating model instead of an unmanaged notebook shortcut.

The best source pages are Biotech, Pharmaceutical, Regulated Execution, and the Policy Controls Catalog. The key lesson is to stop asking for a perfect “novel IP detector” and instead enforce a route that keeps the most sensitive work on the most defensible path.

Implementation​

This route prioritizes local or zero-retention processing, applies explicit identifier filtering, and records the resulting discovery workflow.

pack:
  name: biotech-discovery-ip-guard
  version: 1.0.0
  enabled: true

providers:
  targets:
    - id: local-research-model
      provider: ollama
      model: llama3.1:70b
      base_url: http://localhost:11434
    - id: openai-zdr-discovery
      provider: openai
      model: gpt-5.4-mini-mini
      secret_key_ref:
        env: OPENAI_API_KEY
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0

policies:
  chain:
    - rbac
    - data-routing-policy
    - pii-detector
    - hipaa-phi-detector
    - dlp-filter
    - audit-logger

policy:
  rbac:
    deny_if_missing:
      - X-User-ID
      - X-User-Role

  data-routing-policy:
    require_zero_data_retention: true
    on_no_compliant_provider: block
    log_provider_selection: true

  pii-detector:
    action: redact
    healthcare_mode: true

  hipaa-phi-detector:
    mode: hipaa_18
    action: redact
    safe_harbor_method: true

  dlp-filter:
    detect_patterns:
      - '\bCPD-[0-9A-Z]{6,10}\b'
      - '\bASSAY-[A-Z0-9]{4,12}\b'
      - '\bSTUDY-[0-9]{4,8}\b'
    action: redact

  audit-logger:
    immutable: true
    retention_days: 3650

Two operational rules matter here. First, keep the most novel work on the most constrained route, even if less sensitive drafting work can use a broader provider set. Second, store provider credentials and related secrets in an approved control path such as CLI: secrets rather than sharing them across ad hoc research tooling.

Use Configurations to maintain separate route definitions for discovery, translational, and partner-facing workflows. That keeps teams from pushing all science through the same assistant simply because it already exists.

Results and impact​

Biotech teams get a route they can defend. Researchers still move faster on literature synthesis and early drafting, but the organization no longer has to rely on personal discipline to decide what goes to which model. Route choice, provider posture, and audit evidence are all part of the system.

That tends to improve collaboration as well. Security teams stop being the department that only says no, and research teams stop treating every control as a blocker. A narrow, explicit route for the most sensitive discovery work usually unlocks more adoption than a broad, ambiguous route that nobody fully trusts.

Key takeaways​

  • Novel IP protection is primarily a route-isolation problem, not a magic detection problem.
  • Use data-routing-policy to keep sensitive discovery work on approved providers.
  • Use dlp-filter for known compound, assay, and study identifiers.
  • Add pii-detector and hipaa-phi-detector whenever translational or subject-linked data enters the workflow.
  • Keep the evidence trail with audit-logger so research and security teams can review actual behavior.

Next steps​